ENDP Endo International Plc

Price (delayed)

$5.48

Market cap

$1.26B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.68

Enterprise value

$7.79B

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: U.S. Branded-Specialty & Established Pharmaceuticals, U.S. Branded-Sterile Injectables, U.S. Generic Pharmaceuticals and International Pharmaceuticals. The U.S. Branded-Specialty & Established Pharmaceuticals segment offers prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The U.S. Branded-Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. The U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health and cardiovascular disease markets, among others. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. The company was founded in 1997 and is headquartered Dublin, Ireland.

Highlights

The EPS has soared by 69% YoY and by 2.9% from the previous quarter
ENDP's net income has surged by 69% year-on-year and by 2.2% since the previous quarter
The company's quick ratio rose by 38% YoY but it fell by 2.2% QoQ
The gross profit has increased by 8% year-on-year but it has declined by 3.6% since the previous quarter
Endo International's equity has decreased by 18% YoY and by 9% from the previous quarter
Endo International's revenue has decreased by 3.1% from the previous quarter

Key stats

What are the main financial stats of ENDP
Market
Shares outstanding
230.29M
Market cap
$1.26B
Enterprise value
$7.79B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.43
EV/EBIT
32.82
EV/EBITDA
10.08
EV/Sales
2.68
Earnings
Revenue
$2.91B
EBIT
$237.43M
EBITDA
$773.34M
Free cash flow
$199.52M
Per share
EPS
-$0.68
Free cash flow per share
$0.87
Book value per share
-$3.4
Revenue per share
$12.64
TBVPS
$14.89
Balance sheet
Total assets
$9.17B
Total liabilities
$9.95B
Debt
$8.37B
Equity
-$782.48M
Working capital
$1.51B
Liquidity
Debt to equity
-10.7
Current ratio
2.17
Quick ratio
1.79
Net debt/EBITDA
8.44
Margins
EBITDA margin
26.6%
Gross margin
49.3%
Net margin
-5.3%
Operating margin
9.9%
Efficiency
Return on assets
-1.7%
Return on equity
N/A
Return on invested capital
2.8%
Return on capital employed
3%
Return on sales
8.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ENDP stock price

How has the Endo International stock price performed over time
Intraday
1.86%
1 week
4.18%
1 month
-5.35%
1 year
15.13%
YTD
16.84%
QTD
66.06%

Financial performance

How have Endo International's revenue and profit performed over time
Revenue
$2.91B
Gross profit
$1.43B
Operating income
$289.2M
Net income
-$154.04M
Gross margin
49.3%
Net margin
-5.3%
ENDP's net income has surged by 69% year-on-year and by 2.2% since the previous quarter
Endo International's net margin has soared by 69% YoY
Endo International's operating income has decreased by 13% QoQ
The operating margin has declined by 10% since the previous quarter

Growth

What is Endo International's growth rate over time

Valuation

What is Endo International stock price valuation
P/E
N/A
P/B
N/A
P/S
0.43
EV/EBIT
32.82
EV/EBITDA
10.08
EV/Sales
2.68
The EPS has soared by 69% YoY and by 2.9% from the previous quarter
Endo International's equity has decreased by 18% YoY and by 9% from the previous quarter
ENDP's price to sales (P/S) is 46% lower than its 5-year quarterly average of 0.8 but 43% higher than its last 4 quarters average of 0.3
Endo International's revenue has decreased by 3.1% from the previous quarter

Efficiency

How efficient is Endo International business performance
Endo International's ROA has soared by 66% YoY
Endo International's return on invested capital has decreased by 3.4% QoQ

Dividends

What is ENDP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ENDP.

Financial health

How did Endo International financials performed over time
The company's total assets is 8% lower than its total liabilities
The company's quick ratio rose by 38% YoY but it fell by 2.2% QoQ
Endo International's equity has decreased by 18% YoY and by 9% from the previous quarter
The debt to equity has grown by 16% YoY and by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.